ADORX THERAPEUTICS LIMITEDActive
Key figures
ADORX THERAPEUTICS LIMITED does not disclose its turnover in its latest accounts; the profit for the year is as stated in the accounts.
Ratios
2024/25Balance sheet structure
Dividends
from the accountsDividends paid in the financial year: £3,200,000.
Filed accounts2024/25
| 2024/25 | |
|---|---|
| Profit for the year | 211,002 |
| Cash at bank and in hand | 4,886,329 |
| Total assets | 4,967,039 |
| Total liabilities | 106,694 |
| Net assets / total equity | 4,860,345 |
| Average number of employees | 0 |
| Dividends paid | 3,200,000 |
A dash (—) means no accounts were filed for that year or the item is not in the accounts; 0 is a zero stated in the accounts. Small companies usually file only a balance sheet, so the profit and loss account is often missing.
Principal activity
Accounts 2025The principal activity of the company continued to be that of research and development of therapeutics for cancer and commercialising these therapies.
As described in the company's latest filed accounts.
Summary: ADORX THERAPEUTICS LIMITED
Company
ADORX THERAPEUTICS LIMITED is a private limited company registered with Companies House under company number SC558719. It was incorporated on 24 Feb 2017. Its status is active. The registered office is in Edinburgh (EH2). Its nature of business (SIC 2007) is research and experimental development on biotechnology (72110).
Accounts
The latest accounts in the database are for 2024/25 (period ending 28 Feb 2025); the company files full accounts. Profit for the year was £211,002. Net assets were £4,860,345. Cash at bank and in hand was £4,886,329. Total assets were £4,967,039 and total liabilities £106,694. The company had an average of 0 employees.
Control and charges
2 persons with significant control are registered.
Filing deadlines
The next accounts are due by 30 Nov 2026. The next confirmation statement is due by 10 Mar 2027.